Executive Briefing Series (formerly The Food & Drug Letter)
April 20, 2012
Draft Guidance Reduces Safety Reporting for Some Drug Trials
Drug sponsors may be able to collect less and better-targeted safety data in late-stage or postmarket trials if certain aspects of the safety profile are already well established, according to a new draft guidance.
This article is viewable by subscribers only. To view this article, please select an option below.